Best Clinical Genomics Companies in Germany
The 52 best Clinical Genomics companies in Germany in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Ganymed Pharmaceuticals.
Germany's Clinical Genomics sector is moving fast, and this directory ranks the 52 companies we track there by disclosed equity funding and recent momentum. Total disclosed funding sits at $666M across those companies, with no unicorns yet but some clear standouts: Ganymed Pharmaceuticals leads at $212M raised, followed by Isarna Therapeutics at $158M and Curetis at $127M. That's a concentrated funding pool, and it tells you where institutional conviction has landed. According to 2017 research, genomic data integration is reshaping therapeutic targeting, which maps directly onto what these companies are building. The global clinical genomics market was valued at $24.3B in 2021 and is projected to reach $85.1B by 2030, compounding at 16.37% annually, driven by declining sequencing costs and accelerating demand for personalized medicine.
So what's the texture on the ground right now? Hot themes this quarter include cancer biomarkers, pharmacogenomics, and machine learning drug discovery, and automation is reshaping lab workflows in ways that compress timelines significantly. Investors like HTGF, EIC Fund and Creathor Venture are the most active backers in this geography, I'd watch their portfolio moves as a leading indicator. Germany's regulatory environment adds friction but also credibility for clinical-stage assets, which matters when you're trying to cross borders with a genomic diagnostic.
- Mordor Intelligence
- ResearchAndMarkets.com
Ranked: Best Clinical Genomics companies in Germany
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AdnaGen Genetic diagnostic testing systems for the medical and clinical research laboratories | — | — | — | 1999 | Wolfram Rodatz CEO | — | 68 patents Liquid biopsy platforms for isolating/enriching targets and molecular diagnostics of cells. | — |
| 2 | AGCT Developer of non-invasive liquid biopsy test for cancer diagnosis and treatment | — | — | — | 2016 | Hans Jorg Hess CEO & MD | — | 36 patents Improved nucleic acid amplification methods, reagents, and diagnostic kits for PCR specificity. | — |
| 3 | Ares Genetics Diagnostic solutions for detecting antimicrobial resistance | — | — | — | 2017 | Oliver Schacht CEO | — | — | — |
| 4 | BF- BIO labs Nucleic acid and protein microarray printing services | — | — | — | 2003 | Patric Zeltz CEO | — | — | — |
| 5 | bioactiva Provider of molecular diagnostic tests for various diseases | — | — | 12 12 → 6 (-50%) | 2001 | — | Cart FunctionalityMagentoMySQL+17 | — | — |
| 6 | BioDoc Provider of molecular diagnostic tests for infectious diseases | — | — | — | 2017 | Michael Mahler Founder & Managing Director | — | — | — |
| 7 | BIOTECON Diagnostics Diagnostics products and services | — | — | 51 | 1999 | Kornelia Berghof Jaeger CEO & MD | — | 49 patents Molecular detection assays for foodborne bacterial pathogens in clinical and environmental samples | — |
| 8 | Carpegen Developer of point-of-care diagnostics for the detection of pathogens | — | — | — | 2001 | Antje Roetger Co-Founder & CEO | — | 20 patents Biotech sample analysis and fluid handling systems for chemical/biological testing | — |
Top 12 Clinical Genomics companies in Germany
#1
Public · Mainz, Rhineland-Palatinate · founded 2021 · 64 employees$17.3Mraised▾
Provider of diagnostic kits for colorectal cancer. The company's product ColoAlert is a PCR-based molecular genetic colorectal cancer early-detection stool test. It uses proprietary methods to analyze cell DNA for specific tumor markers combined with the fecal immunochemistry test (FIT) and is designed to detect tumor DNA and CRC cases in their earliest stages.
- Feb 2026Post IPO$3M
- Jun 2023Post IPO$14.3M
#2
Acquired · Holzgerlingen, Baden Wurttemberg · founded 2007 · 55 employees$127.1Mraised▾
Curetis provides a molecular diagnostics device to detect infectious diseases. The company focuses on multiparameter testing of many analytes in a single run, providing broad panels of combined pathogen and resistance gene detection for a wide range of diseases. The company develops the Unyvero A50 System for the detection of bacterial infections using PCR technology in hospitalized patients. Using a variety of cartridges, diseases such as pneumonia or implant and tissue infections can also be diagnosed within 4–5 hours.
- Sep 2020Grant (prize money)$409.7K
- Jul 2020Conventional Debt$5.7M
- May 2019Series C$1.7M
- May 2019Conventional Debt$5.6M
#3
Acquired · Mainz, Rhineland-Palatinate · founded 2001 · 4 employees$212.1Mraised▾
Developer of antibody-based drugs for the treatment of solid cancers. The company focuses on the development of a new class of cancer drugs including IMAB362, an antibody-drug candidate for the treatment of gastroesophageal cancer, and IMAB027, a monoclonal antibody to treat ovarian cancer. Its discovery programs are for breast cancer and solid tumors. It also develops Claudetect18.2, a CE marked in vitro diagnostic test to assess the expression levels of claudin-18.2 in the gastroesophageal, pancreatic, lung, and other solid tumors.
- Nov 2013Series E$57.3M
- Nov 2008Series D$82.8M
- Apr 2007Series C$45.5M
- Jul 2005Grant (prize money)$2M
#4
Series F · Munich, Bavaria · founded 1998 · 3 employees$158.1Mraised▾
Isarna Therapeutics develops TGF-B inhibitors that stimulate the human immune system to effectively treat ophthalmic, fibrotic diseases cancer. Its lead product ISTH0036 for ophthalmology is undergoing Phase 1 trials. Other candidates include ISTH1106 for fibrosis, ISTH0047, and ISTH1047 for oncology which are in pre-clinical stage. Its leading candidate ISTH0036 is a locked nucleic acid-modified antisense oligonucleotide selectively targeting the messenger ribonucleic acid (mRNA) of TGF-β2. The company received FDA orphan drug designation for ISTH0036, for the prevention of scarring post glaucoma filtration surgery.
- Apr 2014Series F$7.6M
- Jan 2014Series F$17.8M
- Jan 2012Series F$11M
- Jul 2011Series E$11.6M
#5
Series B · Freiburg im Breisgau, Baden Wurttemberg · founded 2016 · 74 employees$27.7Mraised▾
SpinDiag, a spin-off of Hahn-Schickard, develops a point-of-care system. The automated system helps in the screening drug-resistant pathogens. The system, LabDisk, is based on a patented centrifugal-microfluidic technology which provides PCR results directly from patient swab samples.
- Oct 2022Conventional Debt$14.6M
- May 2020Series B$17.8M
- Apr 2020Series B$6.5M
- Nov 2018Series A$3.4M
#6
Public · Berlin, Berlin · founded 1998 · 32 employees$53.3Mraised▾
Epigenomics is a molecular diagnostics company developing and commercializing a pipeline of proprietary products for the screening and diagnosis of cancer. Their product portfolio includes Epi proColon®, a blood-based test for the early detection of colorectal cancer and Epi proLung®, a confirmatory test that aids in the diagnosis of lung cancer.Their development pipeline also contains tests for screening, monitoring, diagnosis and prognosis assessment in colorectal and lung cancer.
- Jan 2021Post IPO$6.8M
- Mar 2020Post IPO—
- Nov 2019Post IPO$5.3M
- Jan 2018Grant (prize money)$276.9K
#7
Public · Rostock, Mecklenburg Vorpommern · founded 2006 · 657 employees$28Mraised▾
Provider of biochemical/genetic tests to detect mutations and rare diseases. The company maintains CentoMD, a database of known disease-causing mutations and which includes an advanced phenotype-genotype search tool based on the Human Phenotype Ontology (HPO). The company offers multiple genetic panel tests and single mutation tests. Also, provides analytical services for neonatal testing for congenital and early-onset diseases, and detection of breast cancer, mitochondrial diseases, infertility, stroke and vascular dementia, somatic mutations for cancer, and Fabry's disease.
- Feb 2022Post IPO$16.8M
- Jul 2020Post IPO$28M
- Jun 2017Series A$28M
#8
Deadpooled · Cologne, North Rhine Westphalia · founded 2010 · 40 employees$18.5Mraised▾
Ayoxxa Biosystems developed a technology platform for multiplexed protein analysis. The company's proprietary platform includes Lunaris BioChip that is used to identify and quantify proteins, including markers for cancer, allergies, cardiovascular or infectious diseases. It can be useful in biomedical research, pharmacological screening, and preclinical diagnostics development. The company also offers disease-specific detection kits such as 6-Plex Cytokine Kits to analyze biomarkers that are important in inflammation and in immune regulation.
- Jan 2017Grant (prize money)$21.9K
- May 2015Grant (prize money)$681.5K
- Dec 2014Series B$2.9M
- Jun 2014Series B$12.3M
#9
Public · Jena, Thuringia · founded 2012 · 12 employees$1.4Mraised▾
Developer of epigenetic biomarkers for cancer detection and diagnosis. The company offers GynTect that enables the detection of methylated DNA regions in precancerous and carcinoma cells. These marker regions are detected using PCR-based technologies.
- Sep 2023Series B—
- 2018Series A$868.5K
- 2016Series A$553.6K
- Jan 2015Series A—
#10
Seed · Gauting, Bavaria · founded 2023$544.8Kraised▾
Provider of genomic-based test kits for diisease diagnostics. It offers CRISPR-based platform that enables multiplex detection of DNA and RNA biomarkers with the help of Lateral Flow Assays and PCR for multiple disease diagnosis.
- Aug 2023Seed$544.8K
#11
Funding Raised · Eggenstein Leopoldshafen, Baden Wurttemberg · founded 2018 · 8 employees$2Mraised▾
Aquarray is the provider of droplet microarray technology for clinical application. The droplet microarray is the patented technology for cell cultivation, ultra high throughput screening (uHTS) and biochemical assay platforms. In cell screening, it requires a minimum number of cells that is 1-100 cells.
- Jan 2022Grant (prize money)$55.7K
- Feb 2020Grant (prize money)$1.9M
#12
Acquired · Potsdam, Brandenburg · founded 2004 · 28 employees$8Mraised▾
Signature Diagnostics develops molecular diagnostic products for cancer. Its platform technology uses next generation sequencing and proprietary algorithms for the early detection of cancer. It has two products on the market: OncoDetect for the detection of cell-free tumor DNA in blood, and OncoScout for the detection of tumor DNA from biopsy samples. In Feb 2015, Signature Diagnostics was acquired by Roche for an undisclosed sum.
- Aug 2008Series C$8M
- Jan 2008Series B—
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Clinical Genomics coverage by sub-theme.
Regulatory-risk over time flat
Funding & growth over time
funding rising · growth rising
How research on Diagnostics is moving in Germany
A read on the academic research around Diagnostics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 1,717 Germany-affiliated papers.
- Heidelberg University249
- German Cancer Research Center150
- Charité - Universitätsmedizin Berlin135
- University Medical Center Hamburg-Eppendorf127
- Universität Hamburg107
- Liquid biopsy14→68
- Cancer7→24
- Biomarker2→18
- Biopsy2→16
- DNA sequencing2→14
- Liquid biopsy42→156
- Point-of-care testing40→93
- Biopsy5→52
- Biomarker9→52
- Oncology9→47
- Liquid biopsy19→65
- Biopsy5→31
- Point-of-care testing26→49
- Internal medicine4→19
- Cell-free fetal DNA2→13
Where diagnostics is researched across Germany
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing diagnostics patents in Germany
Germany diagnostics patent filing is steady — 17 filings from 15 assignees (2016–2025), led by Siemens, Roche Diagnostics, Hoffmann LA Roche; annual filings 3→3.
- Siemens7
- Roche Diagnostics5
- Hoffmann LA Roche5
- Fraunhofer GES Forschung3
- Ronda Cornelis R1
- Popov IGOR1
- UNIV Koeln1
- Earlybio1
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.